Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Longbrake EE, et al. Among authors: cascione m. Mult Scler. 2021 May;27(6):883-894. doi: 10.1177/1352458520937282. Epub 2020 Jul 27. Mult Scler. 2021. PMID: 32716690 Free PMC article. Clinical Trial.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
Vermersch P, Oh J, Cascione M, Oreja-Guevara C, Gobbi C, Travis LH, Myhr KM, Coyle PK. Vermersch P, et al. Among authors: cascione m. Mult Scler Relat Disord. 2020 Aug;43:102158. doi: 10.1016/j.msard.2020.102158. Epub 2020 May 13. Mult Scler Relat Disord. 2020. PMID: 32470857 Free article. Review.
Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes✰.
Hunter SF, Thomas FP, Cascione M, Williams IM, Meng X, Schofield L, Weiss JL, Tenenbaum N, Cree BAC; PREFERMS investigators. Hunter SF, et al. Among authors: cascione m. Mult Scler Relat Disord. 2020 Oct;45:102346. doi: 10.1016/j.msard.2020.102346. Epub 2020 Jul 3. Mult Scler Relat Disord. 2020. PMID: 32717684 Free article. Clinical Trial.
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L; EPOC study investigators. Hughes B, et al. Among authors: cascione m. Mult Scler Relat Disord. 2014 Sep;3(5):620-8. doi: 10.1016/j.msard.2014.06.006. Epub 2014 Jul 3. Mult Scler Relat Disord. 2014. PMID: 26265274 Clinical Trial.
Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
Singer B, Wray S, Miller T, Cascione M, Gupta A, Pardo G, Watsky E, Hayward B, Mercer B, Dangond F. Singer B, et al. Among authors: cascione m. Mult Scler Relat Disord. 2012 Apr;1(2):87-94. doi: 10.1016/j.msard.2011.11.002. Epub 2012 Jan 20. Mult Scler Relat Disord. 2012. PMID: 25876936
78 results